Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx věcí,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x., č. 46/2008 Xx. x. x. x x. 47/2012 Xx. x. x. x Mezinárodní xxxxxx proti xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 16. listopadu 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx znění Přílohy X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx.1)
S novým xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x xxxxxxx 34 odst. 3 Xxxxxx xxx 1. xxxxx 2012 x tímto xxxx xxxxxxxxx x xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu platné xx 1. ledna 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx překlad xx českého xxxxxx xx vyhlašují xxxxxxxx.
1) Mezinárodní xxxxxx proti xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 v Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
MEZINÁRODNÍ XXXXXX XXXXX XXXXXXX XX XXXXXX
Příloha X - Seznam xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX KODEX
Xxxxxx xx 1. xxxxx 2012
Xxxxx článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Zakázané xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx látek ze xxxxxx S1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx M1, X2 x X3.
XXXXX X XXXXXX XXXXXXXX XXXXX (PŘI SOUTĚŽI X XXXX XXXXXX) |
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití jakýmkoliv xxxxxxx zdravotnickým regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx stadiu xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), je xxxxxxxx stále.
X1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-androstan-3β,17α-diol | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
xxxxxxx-5-xx-3β,17α-xxxx | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-noretiocholanolon |
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Klenbuterol, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx na xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje x látce, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx vztahuje k xxxxx, xxxxxx může xxxx produkovat přirozeně. |
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx stimulující xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) x Iuteinizační hormon (XX) u xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx faktory (FGFs), xxxxxxxxxxxx xxxxxxx faktor (XXX), insulinu podobný xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx a xxxxxx, krevní zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 agonisté (xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 mikrogramů za 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx v xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx vyšší xxx 30 xx/xx nebude xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx použití, xxx xxxx považována za xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx způsoben xxxxxxxx xxxxxxxxxxxx inhalační dávky xxxxx xxx xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Aminoglutethimid, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, xxxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x omezením pouze xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, ale ne x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Proliferator Xxxxxxxxx Receptor δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx aktivované AMP x xxxxxxxxxxx s XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Soutěži, xxxxxxxx Xxxx Soutěž) jakéhokoliv xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, salbutamol, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou je xxxxxxxxxx xxxxxxx specifické Xxxxxxxxxxxx výjimky xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx látku.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX KYSLÍKU
Xxxxxxxx xx následující:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx autologní, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx produktů jakéhokoliv xxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na hemoglobinu, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx ne x xxxxxxxx xxxxx xx xx. Xxxxxxxx xxxxxxx xxxxxxxx není.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx pokus x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx zakázané. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. proteázami) xxxx, xxx xx x omezením xxxxx xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx než 50 ml za 6 hodin jsou xxxxxxxx kromě infuzí xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx xxxx xx xxxxxxxxx xxxxxxx xx xxxxxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití normálních xxxx geneticky modifikovaných xxxxx;
XXXXX X METODY ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx X5 x X1 xx M3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
S6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx zakázaná, s xxxxxxxx xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), methylendioxyamfetamin, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno x xxxxx odstavci, xx Xxxxxxxxxxx látkou.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, fenbutrazát, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, norfenefrin, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx s podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx látky xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx adrenalinu (xxxx. nosní, oční xxxxxxxx) xxxx jeho xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx není xxxxxxxx.
*** Katin xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 mikrogramů x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx koncentrace x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. KANABINOIDY
Xxxxxxxx (xxxx. hašiš, xxxxxx a xxxxxxxxx) xxxx syntetický xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x kanabimimetika (xxxx. "Spice" /obsahující XXX018, JWH073/ x XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
XXXXX XXXXXXXX V XXXXXXXX XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx sportech. Xxxxxxx xx bude xxxxxxxx xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro porušeni xxxxxxxxxxx pravidla (hematologická xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (WKF)
∙ Xxxxxxx sporty x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (FIM)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Pokud xxxx jinak určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx discipliny) (WCBS)
∙ Bridž (FMB)
∙ Golf (XXX)
∙ Xxxxxxx a xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (FAI)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x snowboard X-xxxxx x "xxx air"
∙ Xxxxxxxx a xxxxxxx sporty (XXXX)
∙ Střelba (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (WDF)
∙ Xxxxx motorismus (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 97/2012 Xx. m. x. xxxxx účinnosti xxxx 25.12.2012.
Xxxxxx předpis x. 97/2012 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx xx 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx předpisu.